Powered by
Read the full press release from BusinessWire here. TAI Diagnostics Announces New Publication using the myTAIHEART® Test in The Journal of Heart and Lung Transplantation TAI Diagnostics, Inc., focused on developing innovative diagnostic tests for monitoring the health of transplanted…
Read the full story from BizTimes here. Madison-based cancer diagnostics company Exact Sciences Corp. completed its $2.8 billion cash-and-stock deal with Redwood City, California-based Genomic Health, the company announced. Exact Sciences produces Cologuard, a noninvasive, at-home screening test that detects the presence…
Read the full press release from BusinessWire here. Imbed Biosciences Inc. (Imbed), a privately held biotech company emerging as a leader in the development of advanced therapies for burns, chronic ulcers and surgical wounds, announced today that it has closed…
Read the full press release from Promentis Pharmaceuticals here. Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced it has successfully completed a behavioral biomarker study for its lead compound, SXC-2023, and has finished enrolling…
Read the full press release on BusinessWire here. TAI Diagnostics, Inc., focused on developing innovative diagnostic tests for monitoring the health of transplanted organs, today announced the publication, “Effect of endomyocardial biopsy on levels of donor-specific cell-free DNA” in the October, 2019…